-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On October 19, the CDE official website showed that Chengdu Kanghong Pharmaceutical's 2.
4 category new drug KH737 eye drops was approved for clinical use, and its indication is to delay the progression of myopia in children
.
According to data from Mi Nei.
KH737 eye drops is a 2.
4-type new drug, and its indication is to delay the progression of myopia in children
.
Since the beginning of this year, Kanghong Pharmaceutical has obtained 4 clinical approvals, including the 2.
According to data from Minai.
Sales of terminal ophthalmic drugs in public medical institutions in China (unit: ten thousand yuan)
Source: Mi Nei.
Kanghong Pharmaceutical’s Conbercept ophthalmic injection was first approved for marketing in 2013.
At present, Kanghong Pharmaceutical's Conbercept has grown into a large variety of 1 billion, and the market size is also continuing to rise.
Data source: Minet database, CDE